• Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

News & Views

Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

Mar 09 2010

Gyros® AB, a leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the signing of a distribution agreement with DI Biotech, a leading supplier to the Korean life-science market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’ proprietary technology, Gyrolab®, to the Korean pharmaceutical, biotech, CRO and CMO industries. Gyrolab has rapidly become established as a preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organisations, in their drug development process and clinical trials, in both Europe and the USA. As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.

“We are very happy to have DI Biotech representing our products in the Korean market”, states Erik Walldén, CEO and President of Gyros. “It’s an organisation with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. S. E. Kim, CEO and President at DI Biotech comments: “We have already tested the market for Gyrolab in Korea, and the response was immediate and positive, which was very encouraging. The benefits that Gyrolab provides are recognised in all sectors of pharmaceutical development, as well as in government-funded institutes. Pharma, biotech and especially, the fast-growing CRO and CMO companies, all see possibilities, to not only ramp-up productivity, but also to boost their competitiveness. The financial standing of these industries was already strong, and coupled with the Korean government’s recent investment of the equivalent of 90 million EUR, to further propel the development of biotherapeutics within the ‘SMART project’, we are extremely optimistic about the rapid uptake and implementation of Gyrolab in Korea.”


Digital Edition

International Labmate 49.6 - Sept 2024

September 2024

Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - From R&D to QC, making NMR accessible for everyone: Putting NMR...

View all digital editions

Events

ICIF China 2024

Sep 19 2024 Shanghai, China

ISSS 2024

Sep 22 2024 Messina, Italy

19th Confocal Raman Imaging Symposium

Sep 23 2024 Ulm, Germany

Control-Tech

Sep 24 2024 Kielce, Poland

WoTS - World of Technology and Science

Sep 24 2024 Utrecht, Holland

View all events